Corona Remedies
Corona Remedies Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
1 of 3 strong
Not discussed on this call: fundraise, order book.
The short version
CORONA Remedies targets 15% organic revenue growth for FY27, with an additional 25% growth expected from inorganic opportunities, totaling about 17% revenue growth overall. - The company aims to sustain double-digit industry growth, anticipating Indian Pharmaceutical Market (IPM) growth around 9%-11% annually. - Volume growth significantly outpaces the IPM, with 6.3% volume growth versus 1.3% for the IPM in MAT June 2026 (approx. CORONA Remedies targets a **15% organic revenue growth** and **20% PAT growth** for FY27 and near-term future.
From Corona Remedies's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- CORONA Remedies targets 15% organic revenue growth for FY27, with an additional 25% growth expected from inorganic opportunities, totaling about 17% revenue growth overall.
- The company aims to sustain double-digit industry growth, anticipating Indian Pharmaceutical Market (IPM) growth around 9%-11% annually.
- Volume growth significantly outpaces the IPM, with 6.3% volume growth versus 1.3% for the IPM in MAT June 2026 (approx. 5x IPM).
- Price-led growth and new product introductions also contribute, with prices growing at 8.7% versus IPM’s 5.6%, and new product introductions at 3.4% versus IPM’s 2.9%.
- Strong ramp-up expected in IVF business over next 2-3 quarters as the MR taskforce scales efforts.
- Export growth anticipated from new EU GMP hormonal plant, with dossiers expected ready by late 2026 and market entry soon after.
- Operating leverage and marketing scale are expected to support sustainable revenue and volume growth over the medium term.
Profitability & Margins
See what Corona Remedies said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Corona Remedies Limited has recently commissioned a new EU GMP approved hormonal manufacturing plant with a capex of INR 130 crores.
- The hormonal plant started operations on June 30, 2026, and is expected to have an asset turnover of less than 1x in FY27, gradually increasing to 2-3x over the next three years.
- The company is in the final stages of preparing dossiers for this plant to enable international market entry, targeting FY28-29 for international scale-up.
- Additional capital investments related to brand acquisitions include the Wokadine brand (acquired for INR 97 crores plus GST), amortized over 10 years, and a Bayer brand acquired for INR 7 crores.
- No specific mention of new capex beyond the hormonal plant was highlighted in the current period, but the company plans ongoing investment in expanding manufacturing and market penetration.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Corona Remedies said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Corona Remedies — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹353 Cr, net profit ₹45 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Corona Remedies Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Corona Remedies Q1 FY27 results?
CORONA Remedies targets 15% organic revenue growth for FY27, with an additional 25% growth expected from inorganic opportunities, totaling about 17% revenue growth overall. - The company aims to sustain double-digit industry growth, anticipating Indian Pharmaceutical Market (IPM) growth around 9%-11% annually. - Volume growth significantly outpaces the IPM, with 6.3% volume growth versus 1.3% for the IPM in MAT June 2026 (approx. CORONA Remedies targets a **15% organic revenue growth** and **20% PAT growth** for FY27 and near-term future.
What is Corona Remedies share price analysis?
Corona Remedies currently shows a below-average growth signal. The stock trades at a P/E of 61.9 with a market cap of ₹13,104 Cr. Investors should review the full earnings analysis for detailed insights.
Is Corona Remedies planning capital expenditure?
Corona Remedies Limited has recently commissioned a new EU GMP approved hormonal manufacturing plant with a capex of INR 130 crores.
Keep Corona Remedies on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.